The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar(Dana-Farber Cancer Institute), Kenneth C. Anderson(Novartis (Switzerland))
Cited by 77
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
|Blood|2002|667
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
|Proceedings of the National Academy of Sciences|2005|596